-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhongguancun (000931.SZ): Application for marketing license for Grello tablets accepted

Zhitongcaijing·09/10/2026 11:41:11
Listen to the news

Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Duoduo Pharmaceutical Co., Ltd. (hereinafter: Duoduo Pharmaceutical), a subsidiary of the company, recently received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration), and the marketing license application for Gurello tablets (specifications: 60mg, 90mg) was accepted.

The indications for tigrello tablets are: This product is used in combination with aspirin to reduce the incidence of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or patients with a history of myocardial infarction and with at least one risk factor for atherosclerotic thrombosis events (see clinical trial PEGASUS study).